| Schedules of loans receivables |
A breakdown of the loans receivable terms and balances are as follows:
|
|
|
|
|
|
|
Loans receivable |
|
September 30, 2022 |
|
December 31, 2021 |
Teneo Fund SPVi LLC note – No interest rate or due date |
|
$ |
5,911 |
|
$ |
5,911 |
Pharma EU, LLC note – Interest rate of 12.0%, due December 31, 2020 |
|
|
1,410 |
|
|
1,410 |
A&R note – No interest rate, due December 31, 2022 |
|
|
711 |
|
|
714 |
SSZ and Elev8 note – Interest rate of 8.0% per annum, due October 8, 2030 |
|
|
1,002 |
|
|
1,002 |
Pure Hana Synergy note – Interest rate of 10.0% per annum, due August 1, 2022 |
|
|
224 |
|
|
224 |
Little Beach Harvest note – Interest rate of 9.0% per annum, due August 24, 2036 |
|
|
1,586 |
|
|
423 |
Total loans receivable |
|
$ |
10,844 |
|
$ |
9,684 |
Less allowance for expected credit losses |
|
|
(6,713) |
|
|
(5,559) |
Loans receivable, net of expected credit losses |
|
|
4,131 |
|
|
4,125 |
Less current portion of loan receivable |
|
|
(888) |
|
|
(2,453) |
Loans receivable, long-term |
|
$ |
3,243 |
|
$ |
1,672 |
|
| Schedule of analysis of credit quality of loans receivable |
The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECLs:
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2022 |
Nature of collateral |
|
Gross amounts |
|
Loan losses |
|
Net |
Security interest in assets of counterparty |
|
$ |
9,210 |
|
$ |
(5,644) |
|
$ |
3,566 |
Third party guarantee |
|
|
1,410 |
|
|
(882) |
|
|
528 |
No collateral |
|
|
224 |
|
|
(187) |
|
|
37 |
Net loans receivable |
|
$ |
10,844 |
|
$ |
(6,713) |
|
$ |
4,131 |
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2021 |
Nature of collateral |
|
Gross amounts |
|
Loan losses |
|
Net |
Security interest in assets of counterparty |
|
$ |
8,050 |
|
$ |
(4,556) |
|
$ |
3,494 |
Third party guarantee |
|
|
1,410 |
|
|
(882) |
|
|
528 |
No collateral |
|
|
224 |
|
|
(121) |
|
|
103 |
Net loans receivable |
|
$ |
9,684 |
|
$ |
(5,559) |
|
$ |
4,125 |
|